Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Lymphoma 4Colorectal Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia 2Xerostomia 1Warts 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tongue Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stomach Neoplasms 1Sezary Syndrome 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non-Small Cell Lung Cancer 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Pain 1

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NETWORK × Mesothelioma × Clear all
NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2/3 Completed
520 enrolled 16 charts 1 FDA
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡